advocacy
BioAlberta works with policymakers at all levels for a coordinated approach to setting public policy initiatives and ensuring the life sciences industry’s critical issues are well represented.
Through our Advocacy and Policy Committee, BioAlberta focuses on legislative and regulatory policy at the provincial level.
However, we also work with partner life science organizations across the country to support federal regulatory issues. Our Advocacy and Policy Committee is divided into subcommittees to answer the unique needs of each of the life science sectors.
Priority activities include:
- Coverage of critical legislation and regulatory policy
- Educating public officials about biotechnology
- Encouraging greater support for life sciences entrepreneurship
- Simplifying the regulatory environment, among other issues
PMPRB
BioAlberta Submission Re: National Rare Disease Strategy
Alberta has been a national leader in rare disease strategy since the inception of the Alberta Rare Diseases Drug Program in 2009, supported by a robust regional infrastructure that includes one of the most comprehensive health system data repositories in Canada (Alberta Health Services),
March 26, 2021
Leaving the Lab: Tracking the Decline in AMR R&D Professionals
The AMR Industry Alliance conducted a review of publicly available data on the state of AMR research and development talent.
February 07, 2024
BioAlberta's Position Paper on Bioenergy Development in Alberta
BioAlberta is pleased to provide this position paper in response to the Government of Alberta’s Emissions
Reduction and Energy Development Plan1 and initiatives in support of advancing bioenergy development in the
province.
August 23, 2023
Investor Tools to Grow Alberta's Plant Protein Sector
This paper is continuation of our work for the plant-based ingredients that we started in 2019 with the assistance of Alberta Innovates that resulted in publishing the industry strategy and preliminary action plan titled Plant-Based Ingredients: Charting a Bold Path Forward.
August 18, 2023
The Patented Medicine Prices Review Board has lost its way (again)
This commentary by W. Neil Palmer argues that the PMPRB has demonstrated little to no interest in patient health or health outcomes. It is time that changed.
November 1, 2022
Leaving the Lab: Tracking the Decline in AMR R&D Professionals
The AMR Industry Alliance conducted a review of publicly available data on the state of AMR research and development talent.
August 23, 2023
BioAlberta's Position Paper on Bioenergy Development in Alberta
BioAlberta is pleased to provide this position paper in response to the Government of Alberta’s Emissions
Reduction and Energy Development Plan1 and initiatives in support of advancing bioenergy development in the
province.
August 23, 2023
Investor Tools to Grow Alberta's Plant Protein Sector
This paper is continuation of our work for the plant-based ingredients that we started in 2019 with the assistance of Alberta Innovates that resulted in publishing the industry strategy and preliminary action plan titled Plant-Based Ingredients: Charting a Bold Path Forward.
August 18, 2023
The Patented Medicine Prices Review Board has lost its way (again)
This commentary by W. Neil Palmer argues that the PMPRB has demonstrated little to no interest in patient health or health outcomes. It is time that changed.
November 1, 2022
